Skip to main content

Table 2 Primary and main secondary outcomes at 12 months

From: Evaluation of effect of cooled haemodialysis on cognition in patients with end-stage kidney disease (ECHECKED) feasibility randomised controlled trial results

 

Standard

Low

Difference in change (p =)

MOCA

N

12

15

 

Baseline

22.5 (17.8–25.8)

25.0 (17.0–26.0)

 

12 months

23.5 (16.5–27.0)

21.0 (15.0–25.0)

0.449

Change from baseline, p

1.0 (-2.8–3.0) p = 0.755

2.0 (-1.0–4.0) p = 0.047

 

HADS Depression

N

12

15

 

Baseline

4.5 (3.0–6.8)

4.0 (3.0–7.0)

 

12 months

5.0 (3.3–5.0)

5.0 (4.0–7.0)

0.236

Change from baseline, p

-0.5 (-2.0–2.8) p = 0.521

0.0 (-3.0–2.0) p = 0.503

 

HADS Anxiety

N

12

15

 

Baseline

2.5 (0.3–6.5)

3.0 (1.0–4.0)

 

12 months

2.5 (1.0–6.0)

4.0 (1.0–7.0)

0.704

Change from baseline, p

-0.5 (-1.0–1.8) p = 0.834

0.0 (-3.0–1.0) p = 0.194

 

AQOL

N

9

12

 

Baseline

47.0 (33.5–52.0)

46.0 (41.5–51.5)

 

12 months

47.0 (41.5–55.0)

47.5 (37.5–52.8)

0.66

Change from baseline, p

-1.0 (-10.0–2.0) p = 0.326

-1.0 (-9.5–8.0) p = 0.859

 

HD Recovery time

N

9

11

 

Baseline (hours)

4 (2–18)

3 (2–6)

 

12 months (hours)

8 (3–12)

4 (2–8)

0.67

Change from baseline (hours), p

0 (-8–2) p = 0.397

0 (-1–4) p = 0.813

 
  1. Data presented as median (IQR)
  2. MoCA – Montreal Cognitive Assessment tool, CAM – Confusion Assessment Method, QoL – quality of life, ADL – activities of daily living, HADS – Hospital Anxiety and Depression Scale, HD – haemodialysis